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Objective: More than 80% of people with multiple sclerosis (MS) are affected by
spasticity. Spasticity is known to reduce quality of life and contribute to additional
symptoms, such as pain and reduced mobility, but the association between spasticity,
balance, and mobility has not yet been established. Our aim was to examine whether
a relationship exists between spasticity in the lower limbs, balance, and gait, as well as
to explore the involvement of different muscle groups.
Methods: This study employed a cross‐sectional design. Thirty patients with MS
were included. The Modified Ashworth Scale (MAS) was used to examine spasticity
in the ankle plantar flexors, knee extensors, and hip adductors. Balance was measured
using the Mini‐Balance Evaluation Systems Test, and gait with the 2‐Minute Walk
Test. The participants were tested once with no additional follow‐up. Spearman's cor-
relation, recursive partitioning, and linear regression analyses were used to explore
the association.
Results: A significant correlation between gait distance and spasticity in the ankle
plantar flexors (ρ = −.69, p < .001) and knee extensors (ρ = −.45, p = .012) was
observed. Balance significantly correlated with spasticity in ankle plantar flexors
(ρ = −.69, p < .001), knee extensors (ρ = −.52, p = .003), and hip adductors (ρ = −.5,
p = .005). The relationship between spasticity in ankle plantar flexors and hip adduc-
tors was significant, even from low levels of spasticity, whereas MAS score ≥ 2 was
clinically correlated with a decrease in gait and balance function. Adjustments for sex,
age, or years since diagnosis had only minor impact on the results.
Conclusions: This study indicates that spasticity in the lower limbs is clinically
significantly associated with mobility in people with MS.
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Multiple sclerosis (MS), the most common disabling neurological illness
among young people, most frequently manifests as an initial
relapsing–remitting course (Cameron & Wagner, 2011). Globally,
approximately 2.5 million people live with the disease. The prevalence
is approximately twice as high in women as in men (Thompson,
Baranzini, Geurts, Hemmer, & Ciccarelli, 2018). The clinical manifesta-
tion largely depends on the topography of the inflammatory lesions in
the central nervous system, although the most frequent symptoms
and signs observed at disease onset originate from the optic nerve,
the brainstem, and the spinal cord. The diagnosis is reached through
a combination of history, clinical findings, results from imaging of the
central nervous system (e.g., magnetic resonance imaging), and labora-
tory results, particularly analyses of the cerebrospinal fluid (Thompson
et al., 2018).
Disturbances and a decline in motor function and mobility often
occur, including gait abnormalities, reduced balance, altered alignment,
range of motion, and coordination, as well as spasticity (Cameron &
Wagner, 2011). Spasticity, a velocity‐dependent increase in muscle
tone (Lance, 1980), is commonly observed. Spasticity affects more
than 80% of people with MS (Barnes, Kent, Semlyen, & McMullen,
2003; Bethoux & Marrie, 2016; Rizzo, Hadjimichael, Preiningerova, &
Vollmer, 2004), with symptoms often appearing approximately 5 years
after diagnosis (Vermersch, 2014). Symptoms mainly affect muscles in
the lower extremities (Bethoux, 2013; Vermersch, 2014), including tri-
ceps surae, hip adductors, and knee extensors (Stokes, 2004, p. 193).
Spasticity impacts and tends to exacerbate other symptoms, such as
pain (Flachenecker, Henze, & Zettl, 2014; Patti & Vila, 2014), sleeping
problems (Bethoux & Marrie, 2016), fatigue, and bladder dysfunction
(Zettl, Henze, Essner, & Flachenecker, 2014). Spasticity may predict
future falls (Gunn, Creanor, Haas, Marsden, & Freeman, 2013;
Nilsagard, Lundholm, Denison, & Gunnarsson, 2009) and is reported
to reduce quality of life in several studies (Arroyo, Massana, & Vila,
2013; Svensson, Borg, & Nilsson, 2014; Zettl et al., 2014). The rela-
tionship between spasticity and mobility has rarely been studied,
despite the high prevalence of spasticity and the documented associ-
ation with other symptoms of MS. Some studies report a limited asso-
ciation between ankle spasticity and gait (Kremer, Van Dillen, &
Wagner, 2014), highlighting muscle weakness as the main factor con-
tributing to impaired mobility (Wagner, Kremer, Van Dillen, &
Naismith, 2014). However, Sosnoff, Shin, and Motl (2010) identified
a significant association between an elevated Hoffmann's reflex in
the soleus muscle and postural sway, providing experimental support
for an association between balance function and spasticity. Spasticity
in different muscle groups of the lower extremities was only measured
in one study (Balantrapu, Sosnoff, Pula, Sandroff, & Motl, 2014) but
dichotomised the presence of spasticity. The association between dif-
ferent grades of spasticity in different muscle groups related to gait
and balance has, as far as we know, not been established. Our aim
was therefore to examine whether (a) a relationship exists between
spasticity in the lower limbs, balance, and gait and (b) to explore the
involvement of different muscle groups.2 | METHODS
2.1 | Design
During a period of 6 months, all patients with MS attending their rou-
tine neurological control visits at Molde Hospital Trust were consecu-
tively considered for inclusion in the study. Neurologists considered
individuals for inclusion on the basis of the following criteria:
1. a definitive MS diagnosis according to the 2010 McDonalds
criteria (Polman et al., 2011);
2. the presence of spasticity in one or more muscles of the lower
extremities that was detected by a clinical examination, subjectively
reported stiffness in the lower extremities that was interpreted as
spasticity by the neurologist, or the use of spasmolytic drugs; and
3. some remaining gait function, specified as a Kurtzke Expanded
Disability Status Scale (EDSS) score ≤ 6.5 (a score of 6.5 indicates
constant bilateral assistance required to walk approximately 20 m
without resting; Kurtzke, 1983).
Patients were excluded if any problems with mobility were caused by
symptoms other than spasticity, as determined by the neurologist, if
diseases other than MS caused the reduction in ambulatory function,
if the EDSS score exceeded 6.5, or if they had cognitive difficulties
that prevented them from providing informed consent or receiving
instructions during testing.
We used a disproportionate selection method in an effort to bal-
ance the number of participants with spasticity at each of the five
Modified Ashworth Scale (MAS) levels. During the inclusion period,
35 individuals were recruited. The neurologists considered patients
on the basis of the inclusion criteria, and the patient's maximal MAS
score at inclusion was reported to the project leader. We extended
the inclusion period to recruit participants with MAS scores of 0 and
4, but by the end of the inclusion period, none of the participants
had a MAS score of 4, despite the stratified selection.2.2 | Procedure
The clinical tests were conducted by four physiotherapists (PTs).
A. D. N. conducted the spasticity measurements. The remaining PTs,
who were trained in the tests and experienced with the patient popu-
lation, conducted the mobility measurements. The testers were
blinded to the results obtained by the other PTs during testing.2.3 | Measurement tools
We used the MAS, a measure of velocity‐dependent resistance on a 6‐
point scale, where 0 represents no increase inmuscle tone and 4 indicates
that the affected muscles are rigid in flexion and extension, to measure
spasticity. The MAS is considered a convenient tool for a clinical setting
and is reported to be useful for clinical assessments of spasticity (Rekand,
2010), is easy to learn and use (Barnes et al., 2003), and has demonstrated
TABLE 1 Characteristics of the participants
Variable (n = 30)
Female, n (%) 21 (70)
Male, n (%) 9 (30)
Age, years: mean (SD) 47.3 (12)
MS type, n (%)
Primary progressive 2 (6.7)
Secondary progressive 5 (16.7)
Relapsing–remitting MS 23 (76.7)
Years since diagnosis, mean (SD) 12 (8)
Used medications to reduce spasticity, n (%) 10 (33.3)
Physiotherapy treatment for MS, n (%) 23(56.7)
Meters walked in the 2MWT, mean (SD) 134 (59.9)
Mini‐BESTest scores, mean (SD) 17 (6.9)
Abbreviations: Mini‐BESTest, Mini‐Balance Evaluation Systems Test; MS,
multiple sclerosis; SD, standard deviation; 2MWT, 2‐Minute Walk Test.
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We performed bilateral tests of hip adductors, knee extensors, and ankle
plantar flexors (Ghotbi, Ansari, Naghdi, & Hasson, 2011).
During the gait and balance tests, participants were allowed to use
any habitual assistance device. We measured gait with the 2‐Minute
Walk Test (2MWT). This test is suitable for measuring mobility in peo-
ple with MS, both with mild and more severe disabilities (Baert et al.,
2014). The patients were instructed to perform the 2MWT as fast as
possible without taking any safety risks, walking 37 m before turning.
They were instructed to take breaks if needed, but they would not
be encouraged to do so or be encouraged in any way during the test.
Patients were instructed to start walking 2 m before the timing started.
We measured balance with the Mini‐Balance Evaluation Systems
Test (Mini‐BESTest), a measurement tool addressing different aspects
of dynamic balance using 14 tasks with scores of 0–3 points each and
a total score ranging from 0 to 28 points (28 representing the best
score possible; Horak, Wrisley, & Frank, 2009). The Mini‐BESTest is
suitable for measuring balance in individuals with neurological dis-
eases (Franchignoni, Godi, Guglielmetti, Nardone, & Giordano, 2015),
and the validated Norwegian version has demonstrated high reliability
(Hamre, Botolfsen, Tangen, & Helbostad, 2017).
Information concerning sex, age, years since diagnosis, type of MS,
use of spasmolytic medications, and any physiotherapy treatment for
MS was collected when the patient arrived for testing.
2.4 | Statistical analyses
We computed the sample size on the basis of the expected correlation
level. Small or medium correlation coefficients (Cohen, 1977) were con-
sidered nonimportant, and the sample size was established to detect a
correlation coefficient of at least .5. With an expected correlation coeffi-
cient of .5 (Rasova, Martinkova, Vyskotova, & Sedova, 2012), we would
reach a power of 80% with 29 participants. The R language for statistical
computing Version 3.4.2 was used for statistical analyses (R CoreTeam,
2017). Categorical variables are presented as frequencies and propor-
tions. The distribution of continuous variables was examined in histo-
grams and quantile‐quantile plots. Normally distributed variables are
presented as means and standard deviations, whereas nonnormally dis-
tributed variables are presented as medians and quartiles.
The highest MAS values for left or right ankle plantar flexors, left
or right knee extensors, and left or right hip adductors were pooled
into muscle group variables. A maximal spasticity variable,
representing the maximal MAS score in any muscle group, was also
used for analysis. The bivariate relationship between the spasticity
variables and gait/balance was first analysed by calculating Spearman's
correlation coefficient, rho (ρ). Then bivariate recursive partitioning
was used to divide the participants into subgroups that explained
the impact of spasticity on gait or balance. A conditional interference
framework was used to determine the statistical interference of the
subgrouping (Hothorn, Hornik, & Zeileis, 2006). Multivariate recursive
partitioning was then used to fit a model that included spasticity in all
three muscle groups. Age, sex, and years since diagnosis were then
included to evaluate the influences of nonmodifiable covariates onthe muscle group model. The relationship between maximal spasticity
and balance was also examined with multivariate recursive
partitioning, and the impact of covariates was evaluated. The associa-
tion between maximal spasticity and gait was consistent with the
assumption of the regression analysis and was described as a linear
function. A multivariate linear regression model was used to evaluate
the impacts of the covariates age, sex, and years since diagnosis.
2.5 | Ethics
All patients provided written consent before participating in the study.
The study was conducted in accordance with the Declaration of Helsinki
(WorldMedical Association, 2013).We submitted the study for review by
the Regional Committees forMedical andHealth Research Ethics, but the
Norwegian Social Science Data (NSD) was considered the relevant insti-
tution for approval. The study was approved by NSD (NSD, ID 43393).3 | RESULTS
During the inclusion period of September 2015–January 2016, thirty‐five
individuals were recruited. Four participants withdrew their consent
because they were unable to participate at the scheduled testing times,
and one person was excluded from the study due to an MS exacerbation
(EDSS score of 8.0). Thus, 30 participants ultimately participated in the
entire study, including 21 women and nine men. They were between 24
and 68 years old, with no significant differences in age relating to sex
(p = .432). Most of the participants had relapsing–remitting MS, and the
mean (SD) time since diagnosis was 12 (8) years, although this varied from
less than 1 to26 years. Descriptive characteristics are listed inTable 1. Ten
individuals used spasmolytic medications, with baclofen being the most
commonly used medication (six individuals), whereas three participants
used cannabidiol‐tetrahydrocannabinol and one participant received bot-
ulinum toxin A treatments. The participants had spasticity scores of 0–3
points on the MAS (Table 2). The median score for the ankles was 1+,









n (%) n (%) n (%) n (%)
MAS score
0 8 (26) 13 (43) 15 (50) 5 (17)
1 6 (20) 7 (23) 11 (37) 6 (20)
1+ 10 (33) 3 (10) 2 (7) 8 (27)
2 6 (20) 4 (13) 2 (7) 8 (27)
3 0 (0) 3 (10) 0 (0) 3 (10)
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knee extensors.
Seven participants (23%) used their habitual assistance device dur-
ing testing (i.e., walker and crutches; Table 1). Based on the descriptive
results of the 2MWT, participants who did not use assistance devices
(23 participants) walked a mean (SD) of 153.1 (52.2) metres, compared
with 72.7 (37.3) metres for patients who used their devices (seven
participants), representing a significant difference in the functional
level (p = .001). The balance results were also significantly different
between the groups stratified by the use of assistance devices (12.1‐
point difference; 19.9 points vs. 7.8 points, p < .001). When exploring
gender‐related differences, women walked a mean of 28 (95% [−19.6,
77.3]) metres less than men, however, not a significant difference
(p = .233). Sex‐related differences in the Mini‐BESTest scores were
not observed (p = .911).FIGURE 1 The relationship between spasticity (Modified Ashworth Scale
individual observations. Box plots are divided according to the results fromThe 2MWT ranged from 33 to 252 m, and the association between
the 2MWT and spasticity was moderate to strong, as shown in Figure 1
a–d.We observed a moderate correlation between spasticity of the ankle
plantar flexors and the 2MWT result (ρ = −.69, p < .001). The recursive
partitioning resulted in two subgroups. The participantswithout spasticity
(MAS = 0) walked a mean (SD) of 203.38 (25.39) metres, whereas partic-
ipants with a MAS score ≥ 1 walked 109.14 (47.45) metres (p = .001).
Spasticity in the knee extensors was also moderately associated with
walking distance (ρ = −.45, p = .012). A significant difference was deter-
mined. The participants with a MAS score ≤ 1+ walked a mean (SD) of
154.1 (51.53) metres, whereas participants with a MAS score of 2 or 3
walked 69.1 (33.38) metres (p = .025). We did not identify any significant
correlation between spasticity in hip adductors and gait (ρ = −.30,
p = .105). Themultivariate analysis indicated a combined effect of spastic-
ity in the ankle plantar flexors and knee extensors on the 2MWT result
(Figure 3). Three different subgroups were identified. If spasticity was
present in the ankle planter flexors, a MAS knee extensor score ≥ 2
resulted in a further decrease in walking distance.
A linear relationship between maximal MAS score of the lower
extremity and the 2MWT result was observed (r = −.77, p < .001),
as shown in Figure 1d. The linear regression analyses showed a
reduction in the walking distance by −36.43 m per 1‐point increase
in the maximal MAS score. Adjustments for age (β = −36.11), sex
(β = −38.98), and years since diagnosis (β = −38.98) had only minor
impacts on this result.
The Mini‐BESTest total score ranged from 2 to 27 points. The cor-
relation analysis revealed a moderate correlation between spasticity in
the ankle plantar flexors and balance, as measured by Mini‐BESTest[MAS]) and gait length (2‐Minute Walk Test [2MWT]). Circles indicate
recursive partitioning. The line indicates a linear regression curve
NORBYE ET AL. 5 of 9(ρ = −.69, p < .001) shown in Figure 2a. The recursive partitioning
resulted in two subgroups. The participants with a MAS score of 0
had a mean (SD) Mini‐BESTest score of 25 (1.6), whereas participants
with a MAS score ≥ 1 received a Mini‐BESTest score of 14.09 (5.71,
p = .002). The correlation between knee extensor spasticity and Mini‐
BESTest scores was moderate (ρ = −.52, p = .003). Similar to the ankle
plantar flexors, two terminal subgroups were identified (Figure 2b). The
participants with MAS scores ≤ 1+ had a mean (SD) Mini‐BESTest
score of 19 (6.12), whereas participants with MAS scores ≥ 2 received
a Mini‐BESTest score of 10.43 (5.5, p = .022). Spasticity in hip adduc-
tors was also related to balance (ρ = −.5, p = .005; Figure 2c). A signif-
icant mean (SD) difference was observed between participants with a
MAS score of 0 and a Mini‐BESTest score of 19.6 (6.66), whereas par-
ticipants with a MAS score ≥ 1 received a Mini‐BESTest score of 14.4
(6.41, p = .043; Figure 2d). The exploratory multivariate recursive
partitioning produced three subgroups (Figure 3). An increased tone
of the ankle plantar flexors resulted in a reduced balance score. Partic-
ipants with a MAS ankle plantar flexor score ≥ 1 in combination with
a MAS knee extensor score ≥ 2 had the lowest Mini‐BESTest scores.
We also identified a significant correlation between Mini‐BESTest
results and the maximal MAS score (independent of
musculature; ρ = −.73, p < .001; Figure 2d). A significant mean
(SD) difference was observed between participants with a maximal
MAS score of 0 or 1, with a mean of 24.36 (1.75), compared with par-
ticipants with a MAS score of ≥1+, with a mean of 12.74 (4.87,
p < .001). This association did not change when age, sex, or time since
diagnosis was included in the model.FIGURE 2 The relationship between spasticity (Modified Ashworth Sca
BESTest]). Circles indicate individual observations. Box plots are divided a4 | DISCUSSION
We identified a strong association between spasticity, gait, and balance
tested with clinical measurement tools. The maximal spasticity score of
the lower extremities moderately correlated with walking distance and
balance. For each increase in the level of spasticity, a significant decrease
in walking distance was observed, whereas a MAS score of ≥1+ resulted
in significantly decreased balance. When analysing separate muscle
groups, only a slight increase in ankle plantar flexor muscle tone (MAS
score ≥ 1) correlated with a decrease in walking distance. An increased
knee extensor tone equivalent to a MAS score ≥ 2 exhibited the stron-
gest correlations with both walking distance and balance. Spasticity in
the hip adductors moderately correlated with balance, whereas no asso-
ciation with walking distance was observed.
The significant correlation between spasticity and gait may indi-
cate that spasticity negatively affects mobility. One explanation for
the impact on gait is alterations in presynaptic inhibition and central
modulation (Nielsen, Anderson, & Sinkjaer, 2000). According to results
from a Danish study, alterations in the stretch reflex threshold in the
ankle (Nielsen et al., 2000) activate triceps surae contraction, thus
negatively affecting the forward movement of the body over the foot
in the early stance phase. Spasticity in the ankle plantar flexors also
leads to an early toe‐off during the early swing phase, in addition to
a suppressed dorsiflexion of the ankle due to a strong activation of
the triceps surae musculature (Nielsen et al., 2000; Pau, Coghe,
Corona, Marrosu, & Cocco, 2015). As shown in our study, spasticity
in knee extensors exerts a strong impact when spasticity is classifiedle [MAS]) and balance (Mini‐Balance Evaluation Systems Test [Mini‐
ccording to the results from recursive partitioning
FIGURE 3 The classification tree from the multivariate recursive partitioning. Recursive partitioning classified participants into dichotomous
subgroups on the basis of the exploratory variables. Predictor variables were the Modified Ashworth Scale (MAS) scores for ankle plantar
flexors (MAS‐ankle) and knee extensors (MAS‐knee). Modelling for the two different dependent variables, the 2MWT and Mini‐BESTest resulted
in equal classification trees. Both analyses are therefore presented in the same figure. Means (standard deviations) for each dependent variable are
provided for each subgroup
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cular activation during gait (Coghe et al., 2015; Pau et al., 2015), and
spasticity in the knee extensors leads to an overall reduction in knee
flexion during walking (Pau et al., 2015). In a study reporting treatment
effects of cannabidiol‐tetrahydrocannabinol (Coghe et al., 2015), the
authors note that a reduction in spasticity in the quadriceps muscula-
ture was the dominant factor contributing to gait improvement. The
clinical significance of knee extensor spasticity is also highlighted in
our study. Our results are consistent with those of other studies,
implying that spasticity in the ankle musculature disturbs gait in the
early stages, whereas proximal muscles have a larger impact on gait
in the presence of moderate or severe spasticity. We did not identify
significant associations between spasticity in hip adductors and gait,
despite previous findings that hip adductors are commonly affected
in people with MS (Coghe et al., 2015; Pau et al., 2015). However, only
four participants had a spasticity score > 1 in the adductors, which lim-
ited further analyses.
In contrast to a recent study concluding that spasticity is not cor-
related with the risk of falls or represents a contribution to dynamic
stability (Peebles, Bruetsch, Lynch, & Huisinga, 2017), we observe a
significant correlation between spasticity and the balance variables,
although the results were not linear. We chose Mini‐BESTest as mea-
surement tool, which examines different aspects of balance, including
dynamic balance (Horak et al., 2009). A cut‐off of 19 points on the
Mini‐BESTest has been proposed (Mak & Auyeung, 2013). Using this
cut‐off, our population displays a high risk of falling. According to
another study, the risk of falling increased by 14% for each increase
in the MAS score (Nilsagard et al., 2009). The results from our study
corroborate the findings in Nilsagard et al. (2009) that spasticity, par-
ticularly in the triceps surae and hip adductors, negatively affects bal-
ance in subjects even with low levels of spasticity. As shown in
Figures 1 and 2, the association between spasticity and balance is
greater than the association between spasticity and gait throughout
the different muscle groups. Spasticity in the ankle plantar flexors
and hip adductors exhibited the same pattern in balance, whereas
knee extensors increased the strength of the association in patientswith a MAS score≥ 2. On the basis of these results, our study contrib-
utes to the determination of a clinically significant cut‐off for spastic-
ity in different muscle groups in future studies.
To the best of our knowledge, the significant correlation between
spasticity in different muscle groups and mobility in our study has not
been reported previously. Most studies have investigated the pres-
ence of spasticity in the ankle musculature (Balantrapu et al., 2014;
Kremer et al., 2014; Sosnoff et al., 2010; Sosnoff, Gappmaier, Frame,
& Motl, 2011). Using the Mini‐BESTest, spasticity in the ankle plantar
flexors and hip adductors negatively influenced balance in participants
with a MAS score ≥ 1, with a mean change of more than 10 points in
the ankle plantar flexors and 5.2 points in the adductors per increase
in MAS score. As a change of 4 points or more reflects a clinical
change (Godi et al., 2013), we consider this finding important. Similar
to the gait results, spasticity in the knee extensors significantly
affected balance when the muscle tone was increased throughout
the range of motion (MAS ≥ 2). When spasticity was evident in sev-
eral muscle groups (Figure 3), we identified a mean reduction in bal-
ance exceeding 5 points. The significant correlation between
spasticity in ankle plantar flexors and mobility is potentially explained
by alterations in the ability to efficiently use the ankle strategy, as
spasticity is thought to affect this mechanism (Sosnoff et al., 2010).
The ankle strategy is one of the strategies that is first activated when
balance is challenged, and thus, spasticity‐induced alterations in mus-
cle activation influence balance in patients even with low levels of
increased muscle tone. In mediolateral sway, the hip abductors and
adductors are most active (Shumway‐Cook & Woollacott, 2012). In
people with MS, the increase in postural sway mainly occurs in the
mediolateral direction (Sosnoff et al., 2010), which is associated with
the risk of falling (Cameron & Lord, 2010). This finding may explain
why spasticity in the knee extensors does not significantly impact bal-
ance before moderate spasticity is evident.
Several factors may have affected our results. Because we used a
convenient sample, the results are prone to selection bias and are
not representative of the general population of people with MS.
Although we identified a significant correlation between spasticity,
NORBYE ET AL. 7 of 9gait, and balance, the cross‐sectional design makes the interpretation
of the direction of the association difficult. Paresis or weakness in
the muscle groups (Wagner et al., 2014), in combination with changes
in proprioceptive, vestibular, and visual signals (Brichetto, Piccardo,
Pedulla, Battaglia, & Tacchino, 2015), is associated with reduced
ambulatory abilities and balance. Although we tried to eliminate these
factors by applying defined exclusion criteria, these symptoms were
not examined specifically during testing. Thus, we are unable to con-
clude that the results from our study were not biased by other MS
symptoms. In the inclusion criteria, we also excluded participants with
a high symptom severity (described as an EDSS score > 6.5), but the
EDSS score was not recorded specifically. Because of this, we do
not know how the MS severity differed between the participants.
Additionally, 10 individuals in this study used spasmolytic medica-
tions, which may have reduced spasticity during testing without neces-
sarily improving the results associated with the clinical mobility
variables, as reported in some studies (Nielsen et al., 2000; Orsnes,
Sorensen, Larsen, & Ravnborg, 2000), and may have affected the
strength of the association. However, we performed a stratified analysis
to determine whether spasticity medications altered the results, but the
participants who were on medication showed the same trends as the
patients who were not taking medication. Participants who were on
medication did not diverge from the results of other participants, and
thus, this comparison has not been emphasized in the results chapter.
The small sample size is another limitation. Although sufficiently
powered to ensure internal validity, the results should be generalized
with caution. Notably, significant skewing is observed in the popula-
tion (70% women); however, the uneven sex distribution in patients
with MS is well known, and thus, the results related to sex, in particu-
lar, must be interpreted as trends.
Spasticity was measured with the MAS, a measurement tool that
has been discussed for its clinical relevance (Arroyo et al., 2013;
Rekand, 2010; Sosnoff et al., 2011) and its lack of ability to differenti-
ate the reasons for increased resistance of movement (Johnson, 2002).
In other studies, MAS showed good correlations with self‐reported
spasticity (Arroyo et al., 2013), although its reliability has been
questioned (Ghotbi et al., 2011).4.1 | Implications for physiotherapy practice
Physiotherapy is often viewed as an additional treatment option to
pharmacological management, normally focusing on functions affected
by spasticity. In one Cochrane review (Amatya, Khan, Mantia,
Demetrios, & Wade, 2013), the authors reported the strongest evi-
dence for reduced spasticity when physiotherapy was combined with
a pharmacological intervention. Some studies claim that spasticity is
beneficial to patients (Newsome et al., 2017; Satkunam, 2003) and
should be treated only when imposing restrictions to the individual.
As indicated in the present study, even low levels of spasticity may
limit function. Based on accumulating evidence, spasticity is a common
manifestation in people with MS (Rizzo et al., 2004), occurs early after
diagnosis (Patti & Vila, 2014; Vermersch, 2014), increases impairmentthroughout the lifespan (Kister et al., 2013), is associated with pain,
and exerts a substantial impact on quality of life and daily activities
(Flachenecker et al., 2014). People with MS rate walking ability and
ambulation as the most important functions, independent of MS
severity (Heesen et al., 2008). Despite the conflicting evidence
regarding the association between spasticity and gait (Balantrapu
et al., 2014; Balantrapu, Sandroff, Sosnoff, & Motl, 2012; Kremer
et al., 2014; Peebles et al., 2017; Sosnoff et al., 2011; Wagner et al.,
2014), people with MS have reported restricted mobility to be one
of the most disturbing symptoms of spasticity (Flachenecker et al.,
2014). Spasticity was a predictor of future falls (Nilsagard et al.,
2009) and exacerbated overall disability (Flachenecker et al., 2014) in
several studies.
In conclusion, our data provide a strong indication for an important
relationship between spasticity and gross motor function. Future stud-
ies should explore whether spasmolytic medications and physiother-
apy treatments aimed at reducing spasticity improve gait and
balance function in subjects with MS. Physiotherapists are experi-
enced in evaluating both spasticity and mobility, and an awareness
of spasticity in the early stages may help prevent secondary complica-
tions associated with the symptom.
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